Compugen Ltd. Share Price TEL AVIV STOCK EXCHANGE

Equities

CGEN

IL0010852080

Biotechnology & Medical Research

Delayed TEL AVIV STOCK EXCHANGE 09:57:38 22/05/2024 BST 5-day change 1st Jan Change
680 ILa +1.49% Intraday chart for Compugen Ltd. -14.82% -1.16%

Financials

Sales 2024 * 37.04M 13.59B 2.91B Sales 2025 * 41.12M 15.08B 3.23B Capitalization 167M 61.09B 13.08B
Net income 2024 * -4M -1.47B -314M Net income 2025 * -1M -367M -78.56M EV / Sales 2024 * 4.5 x
Net cash position 2024 * - 0 0 Net cash position 2025 * - 0 0 EV / Sales 2025 * 4.05 x
P/E ratio 2024 *
-37.2 x
P/E ratio 2025 *
372 x
Employees 68
Yield 2024 *
-
Yield 2025 *
-
Free-Float 94.62%
More Fundamentals * Assessed data
Dynamic Chart
1 day+1.49%
1 week-14.82%
Current month-7.77%
1 month-9.27%
3 months-23.66%
6 months+181.46%
Current year-1.16%
More quotes
1 week
640.00
Extreme 640
824.00
1 month
640.00
Extreme 640
825.00
Current year
640.00
Extreme 640
1 175.00
1 year
208.10
Extreme 208.1
1 175.00
3 years
208.10
Extreme 208.1
2 996.00
5 years
208.10
Extreme 208.1
6 766.00
10 years
208.10
Extreme 208.1
6 766.00
More quotes
Managers TitleAgeSince
Chief Executive Officer 57 31/12/01
Director of Finance/CFO 61 31/10/22
Chief Tech/Sci/R&D Officer - 31/12/14
Members of the board TitleAgeSince
Chairman 65 01/10/17
Director/Board Member 68 10/06/18
Director/Board Member 57 10/06/18
More insiders
Date Price Change Volume
22/05/24 680 +1.49% 4 362
21/05/24 670 -4.30% 387,220
20/05/24 700.1 -9.62% 107,818
19/05/24 774.6 -3.01% 32,867
16/05/24 798.6 +0.04% 84,446

Delayed Quote TEL AVIV STOCK EXCHANGE, May 22, 2024 at 09:57 am

More quotes
Compugen Ltd. is a therapeutic discovery company. The Company focuses on infrastructure to discover drug targets and develop therapeutics. The Company is engaged in the research, development and commercialization of therapeutic and product candidates. The Company's pipeline primarily consists of early and preclinical stage immuno-oncology programs based on drug targets discovered by the Company, primarily immune checkpoint and myeloid protein target candidates. These programs are focused on the development of cancer immunotherapy drugs with potential to harness the immune system to provide treatment solutions in areas of unmet medical needs in various cancer types and patient populations, both as monotherapy and in combination with other drugs. Its pipeline also includes a preclinical stage fusion protein autoimmune product candidate. Its fields of focus are oncology and immunology, with emphasis on its discovery capabilities on immuno-oncology.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
3
Last Close Price
1.86 USD
Average target price
5 USD
Spread / Average Target
+168.82%
Consensus